Alternatives to Recursion Pharmaceuticals

AI-native drug discovery: phenomics, robotics, and a 50+ petabyte dataset to de-risk medicines.

End-to-end generative AI drug discovery platform from target ID to clinical trials, validated by a Phase III pipeline.

Causal AI for human health, turning 20+ petabytes of cellular data into targeted therapeutics.

AI-driven drug discovery platform combining 50+ PB of proprietary data with automated wet labs to design and validate optimized molecules.

Tech-driven drug discovery and biologics manufacturing platform

Highly selective small-molecule drug discovery for oncology, immunology, and metabolic diseases.

Oncology real-world evidence platform turning patient data into AI-powered insights for cancer research and care.

All-in-human AI foundation models for precision neurology and CNS drug discovery

Generative AI and robotics for autonomous drug discovery, compressing the DMTA cycle to under two years.

AI-driven clinical trial patient matching and recruitment from EMR data.

Physics-based molecular discovery platform for drug and materials design

AI-powered precision oncology platform analyzing clinical and molecular data for personalized cancer care.

AI drug discovery knowledge graph for target identification and drug repurposing.

AI co-scientist for biomedical research: multi-omics, drug discovery, and lab protocol reasoning

AI-driven CRISPR platform revealing causal disease-driving RNA pathways for immunology and oncology drug discovery

AI foundation models predicting patient drug response to de-risk clinical trials

Open-source AI drug discovery assistant for molecular research

AI-driven health data platform uniting patient care and clinical research

Domain-specific clinical data and RL environments for healthcare AI

AI real-world evidence generation from clinical data in minutes

Cloud ELN, LIMS, and AI platform that unifies biotech R&D data.

FDA-cleared AI for cancer pathology diagnostics and biomarker discovery.

Regulatory-cleared quantitative imaging biomarkers from MRI, CT, and PET for radiology and biopharma

ML-guided protein engineering platform for multi-property co-optimization with compounding models from your own experimental data

AI-driven biomanufacturing for personalized stem cell therapies

Enterprise AI pathology platform for diagnostics and drug development.

Agentic AI for multimodal R&D data analysis and workflow automation

AI data analyst for bio labs: raw data to publication-ready results

AI scientist delivering defendable drug program decisions in 2–5 days.

AI-powered patient identification for clinical trials — daily EHR scans, email alerts for eligible patients.